TABLE 3

Duration of ceritinib treatment according to duration of follow-up in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC)

All evaluable ALK+ patients#Patients with follow-up ≥6monthsPatients with follow-up ≥12months
Subjects n18213671
Duration months5.86.88.1
3.9 (0.4–23.0)5.5 (0.4–23.0)5.5 (0.4–23.0)

Data are presented as mean or median (range) unless otherwise stated. #: discontinuation of ceritinib was documented for 117 out of 182 patients (64.2%) at the cut-off (64.3% maturity); : 16 out of 71 patients (22.5%) were still receiving ceritinib or were censored at cut-off (77.5% maturity).